Merck & Co (MRK) DIvidends Date & History

Key Takeaways

• Dividend yield: MRK offers a dividend yield of roughly 2.3% to 2.4%, modest but above the healthcare sector average of about 1.5%.
• Dividend per share: Merck pays a quarterly dividend of $0.85 per share, or approximately $3.40 per share annually.
• Growth streak: The company has increased its dividend for roughly 15 consecutive years, with a five-year average annual growth rate of about 5.75%.
• Coverage: While the reported earnings payout ratio appears elevated due to one-time accounting charges, cash-flow coverage remains healthy.
• Investor appeal: Merck is best viewed as a dividend growth stock rather than a high-yield or income-focused holding.

Dividend Overview

Merck & Co., Inc. (MRK) is a global pharmaceutical leader best known for its oncology franchise, including the blockbuster immunotherapy Keytruda. The company maintains a disciplined, shareholder-friendly dividend policy, paying a quarterly dividend of $0.85 per share, which translates to roughly $3.40 per share on an annualized basis.

At recent share prices, the dividend yield sits in the low-to-mid 2% range—slightly above the healthcare sector average but well below what a pure income investor might seek. Merck is therefore best characterized as a dividend growth stock: its payments are consistent and gradually rising, rather than exceptionally high. Dividends are paid quarterly, and the company has a long track record of annual increases, making it a candidate for investors focused on compounding dividend income over time rather than maximizing current yield.

Dividend History and Growth

Merck has demonstrated a reliable commitment to returning capital to shareholders. The company has raised its dividend for roughly 15 consecutive years, and its five-year average annual dividend growth rate stands at approximately 5.75%. The most recent increase came in late 2025, when the quarterly payment rose from $0.81 to $0.85 per share.

Looking back over the past several years, the progression has been steady: $0.69 per quarter in 2021-2022, $0.73 in 2023, $0.77 in 2024, $0.81 in 2025, and $0.85 in 2026. This consistent, single-digit growth pattern reflects a mature pharmaceutical business generating strong cash flow. The next ex-dividend date is scheduled for September 15, 2026, with a payment date of October 7, 2026, following the company's standard quarterly cycle.

Dividend Sustainability and Payout Ratio

On a reported, trailing-twelve-month basis, Merck's payout ratio can appear distorted—some data providers show it above 200% of earnings. This is largely the result of significant non-cash charges and one-time items in recent periods rather than a fundamental strain on the dividend.

A more meaningful measure is free cash flow coverage. Merck's dividend consumes roughly 30% to 60% of its free cash flow depending on the period, a level generally considered comfortable and sustainable. Forward earnings estimates likewise point to a payout ratio in the mid-30% range, indicating that the dividend should normalize to a well-covered level as one-time charges roll off. Combined with Merck's strong balance sheet and diversified product portfolio, these factors suggest the dividend remains secure, though investors should monitor earnings trends around patent expirations for Keytruda later this decade.

Dividend Compared to Industry Peers

Within the pharmaceutical and healthcare sector, Merck's dividend profile sits in the middle of the pack. Its yield of roughly 2.3% to 2.4% is higher than that of LLY (Eli Lilly), which pays well under 1%, but lower than income-oriented peers such as PFE (Pfizer) and BMY (Bristol Myers Squibb), which offer yields above 4%. It is broadly comparable to JNJ (Johnson & Johnson) and ABBV (AbbVie), which yield around 3% to 4%.

In this context, Merck's dividend is neither the highest nor the lowest among its large-cap pharmaceutical rivals. Its appeal lies in the combination of a modest but dependable yield, a decade-plus growth streak, and a growth rate that has outpaced the industry median.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and other market opportunities far more efficiently than manual screening. Whether you are searching for reliable dividend payers or high-growth opportunities, the AI Screener offers a structured way to narrow the universe to investments that match your criteria.

Is This Stock Attractive for Dividend Investors?

Merck is likely to appeal most to dividend growth investors and long-term, total-return-focused shareholders rather than investors seeking maximum immediate income. Its yield in the low-to-mid 2% range is modest, but the company's 15-year streak of dividend increases, roughly 5.75% annualized growth, and healthy free cash flow coverage make it a reasonable candidate for investors aiming to build compounding income over many years.

Conservative, buy-and-hold investors may also find Merck's large-cap stability and pharmaceutical cash generation attractive. However, income-focused investors who prioritize current yield may find higher payouts elsewhere in the sector. As with any investment, prospective shareholders should weigh the company's longer-term earnings outlook—particularly around patent expirations and pipeline development—against its dividend record. The balance of evidence suggests Merck is a dependable, if not exceptional, dividend payer, best suited to patient investors with a multi-year horizon.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations